548 related articles for article (PubMed ID: 33603158)
21. Strategies to genetically engineer T cells for cancer immunotherapy.
Spear TT; Nagato K; Nishimura MI
Cancer Immunol Immunother; 2016 Jun; 65(6):631-49. PubMed ID: 27138532
[TBL] [Abstract][Full Text] [Related]
22. CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success.
Long KB; Young RM; Boesteanu AC; Davis MM; Melenhorst JJ; Lacey SF; DeGaramo DA; Levine BL; Fraietta JA
Front Immunol; 2018; 9():2740. PubMed ID: 30559740
[TBL] [Abstract][Full Text] [Related]
23. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
Hong M; Clubb JD; Chen YY
Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
[TBL] [Abstract][Full Text] [Related]
24. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
Morgan MA; Büning H; Sauer M; Schambach A
Front Immunol; 2020; 11():1965. PubMed ID: 32903482
[TBL] [Abstract][Full Text] [Related]
25. Prospects for adoptive immunotherapy of pancreatic cancer using chimeric antigen receptor-engineered T-cells.
Alrifai D; Sarker D; Maher J
Immunopharmacol Immunotoxicol; 2016; 38(1):50-60. PubMed ID: 26473647
[TBL] [Abstract][Full Text] [Related]
26. Engineering T cells for immunotherapy of primary human hepatocellular carcinoma.
Caraballo Galva LD; Cai L; Shao Y; He Y
J Genet Genomics; 2020 Jan; 47(1):1-15. PubMed ID: 32089500
[TBL] [Abstract][Full Text] [Related]
27. T-cells "à la CAR-T(e)" - Genetically engineering T-cell response against cancer.
Eisenberg V; Hoogi S; Shamul A; Barliya T; Cohen CJ
Adv Drug Deliv Rev; 2019 Feb; 141():23-40. PubMed ID: 30653988
[TBL] [Abstract][Full Text] [Related]
28. Current strategies to improve the safety of chimeric antigen receptor (CAR) modified T cells.
Yang QY; Yang JD; Wang YS
Immunol Lett; 2017 Oct; 190():201-205. PubMed ID: 28837818
[TBL] [Abstract][Full Text] [Related]
29. Chimeric antigen receptor-engineered T cells for liver cancers, progress and obstacles.
Li K; Lan Y; Wang J; Liu L
Tumour Biol; 2017 Mar; 39(3):1010428317692229. PubMed ID: 28347250
[TBL] [Abstract][Full Text] [Related]
30. An Update on Adoptive T-Cell Therapy and Neoantigen Vaccines.
Ott PA; Dotti G; Yee C; Goff SL
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e70-e78. PubMed ID: 31099621
[TBL] [Abstract][Full Text] [Related]
31. Advances in Engineering Cells for Cancer Immunotherapy.
Xu X; Li T; Shen S; Wang J; Abdou P; Gu Z; Mo R
Theranostics; 2019; 9(25):7889-7905. PubMed ID: 31695806
[TBL] [Abstract][Full Text] [Related]
32. Evolution of chimeric antigen receptor (CAR) T cell therapy: current status and future perspectives.
Lee YH; Kim CH
Arch Pharm Res; 2019 Jul; 42(7):607-616. PubMed ID: 30830661
[TBL] [Abstract][Full Text] [Related]
33. Advances in T-cell Immunotherapies.
Stroncek DF; Reddy O; Highfill S; Panch SR
Hematol Oncol Clin North Am; 2019 Oct; 33(5):825-837. PubMed ID: 31466607
[TBL] [Abstract][Full Text] [Related]
34. Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells.
Hiltensperger M; Krackhardt AM
Front Immunol; 2023; 14():1121030. PubMed ID: 36949949
[TBL] [Abstract][Full Text] [Related]
35. How to train your T cell: genetically engineered chimeric antigen receptor T cells versus bispecific T-cell engagers to target CD19 in B acute lymphoblastic leukemia.
Ruella M; Gill S
Expert Opin Biol Ther; 2015 Jun; 15(6):761-6. PubMed ID: 25640460
[TBL] [Abstract][Full Text] [Related]
36. Treating cancer with genetically engineered T cells.
Park TS; Rosenberg SA; Morgan RA
Trends Biotechnol; 2011 Nov; 29(11):550-7. PubMed ID: 21663987
[TBL] [Abstract][Full Text] [Related]
37. Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy.
Liu L; Sommermeyer D; Cabanov A; Kosasih P; Hill T; Riddell SR
Nat Biotechnol; 2016 Apr; 34(4):430-4. PubMed ID: 26900664
[TBL] [Abstract][Full Text] [Related]
38. Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells.
Berry LJ; Moeller M; Darcy PK
Tissue Antigens; 2009 Oct; 74(4):277-89. PubMed ID: 19775368
[TBL] [Abstract][Full Text] [Related]
39. Adoptive cancer immunotherapy using genetically engineered designer T-cells: First steps into the clinic.
Eshhar Z
Curr Opin Mol Ther; 2010 Feb; 12(1):55-63. PubMed ID: 20140817
[TBL] [Abstract][Full Text] [Related]
40. Redirected T cells in cancer therapy.
Sangiolo D
Expert Opin Biol Ther; 2015; 15(12):1667-70. PubMed ID: 26515608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
